EyePoint H1 Net Loss Widens to $179.3M; Revenue Drops to $1.2M
EyePoint, Inc. reported a significant widening of its net loss to $179.3 million for the first six months of 2026, compared to $104.6 million in the same period of 2025, while total revenues dropped substantially to $1.2 million from $29.8 million. The company increased its research and development expenses to $155.8 million, reflecting ongoing investment in its pipeline. EyePoint maintains a liquidity position of $180.5 million in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least the next twelve months. Key clinical milestones include the anticipated data readout for DURAVYU's wet AMD Phase 3 trials in August 2026 and the completion of enrollment for DME Phase 3 trials in July 2026.
Key Highlights
- Net loss for the six months ended June 30, 2026, widened to $179.3 million from $104.6 million in 2025.
- Total revenues for the six months ended June 30, 2026, decreased to $1.2 million from $29.8 million in 2025.
- Research and development expenses increased to $155.8 million for the six months ended June 30, 2026.
- Cash, cash equivalents, and marketable securities totaled $180.5 million as of June 30, 2026.
- DURAVYU wet AMD Phase 3 data readout is expected in August 2026.
- DME Phase 3 trials completed enrollment in July 2026, with data expected in Q4 2027.
- Sold 1.43 million shares for $20.2 million under ATM facility during Q2 2026.
- Stockholders approved increasing shares for issuance by 4.9 million under the 2023 Plan.
Price Impact
More from EYPT